Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) shares dipped on Monday (October 21) after it confirmed an extension of a share lockup from insiders.

The Massachusetts-based cannabis firm told investors that a core group of shareholders that owns about three-quarters of Curaleaf’s issued and outstanding shares will extend a planned lockup agreement staggered on different dates.


The company’s share price had fallen 7.3 percent to C$7.65 by 11:15 a.m. EDT on Monday from an opening price of C$8.25. As of 12:51 p.m. EDT, Curaleaf sat at C$7.89.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The new agreement will limit the number of shares released in the lockup to 15 percent as of Monday. Moving forward, an additional 15 percent of the locked-up shares will be made available at the end of each subsequent calendar quarter. The final 10 percent of the shares will be released on March 31, 2021.

Since Curaleaf’s reverse takeover transaction in October 2018, all shareholders owning more than 1 percent of the company’s issued and outstanding shares have been under lockup agreements.

Curaleaf Executive Chairman Boris Jordan said in a statement that the lockup is a marker of continued support from shareholders.

“We expect the new lock-up release schedule to reduce uncertainty regarding the release of currently locked-up shares and provide for a more orderly increase in the available float in the Company’s shares.”

Cannabis companies look to improve market reputation

Curaleaf isn’t alone in trying to instill confidence in investors in an industry that’s seen a degree of volatility recently.

In July, Acreage Holdings (CSE:ACRG.U,OTCQX:ACRGF) CEO Kevin Murphy bought 154,000 shares of the company on the open market for more than US$2 million.

“With the downturn in industry stock prices recently, this was an opportunity to show investors that Acreage management is committed to creating long-term shareholder value,” Murphy said.

British Columbia-based Tilray (NASDAQ:TLRY) also locked up its shares with its investor Privateer Holdings, extending its existing lockup of 75 million shares.

As a part of a downstream merger, Tilray is to acquire Privateer and replace shareholders’ Privateer shares with Tilray shares. The new shares will be locked up for a two year period barring any special considerations.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: Acreage Holdings is a client of the Investing News Network. This article is not paid-for content. 

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Keep reading... Show less

THC-O-Acetate to be Produced Through Company’s Specialty Molecule Division

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), an extraction company that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacturing of CBD-O-acetate and the recently announced U.S. patent for the synthesis of THC-O-acetate.

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (the “Company”) is pleased to announce that it has completed construction of an industrial-grade distribution site and launched third party distribution services.

As part of its Phase 1 Construction project at the 196,000 square foot facility, the Company has built out 16,000 square feet of retail-ready product storage space, installed automated, assembly-line style packaging equipment for jar and pouch production, and built out a climate-controlled area that can store 30 tractor-trailer loads of cannabis and 230 pallets positions of -40 degree Fahrenheit freezers for storing live resin and live resin products. A secure loading bay and a small in-house fleet of refrigerated trucks is also in place.

Keep reading... Show less

Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“GWS” or the “Company”) is pleased to provide the following corporate update highlights on two portfolio clients KaleidoMyco LLC and Biominerales Pharma Corp. and announces the signing of the one-stop digital marketing team of North Equities Corp.

“With the talent, skills and resources we have at Global Wellness, we are well positioned to develop leading nutraceutical product portfolio brands focused on health and well-being. As hemp-extract and psilocybin is legalized in more jurisdictions such as Oregon where we already have a strong strategic relationship, we can then easily extend our existing product range, which will already have established routes to market and brand recognition, to include myco-dosing products. KaleidoMyco products will be in stores and on a consumer digital platform in the USA shortly and is currently being consumer tested in Europe as well. Our shareholders and customers are extremely important to us and we look forward to meeting the milestones we have outlined with the help of North Equities,” said Meris Kott, CEO.

Keep reading... Show less

VINIA(R)’s ability to increase dilation of arteries and to reduce blood vessel constriction allows it to fight the human aging process

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) announces that its flagship VINIA® product is the only dietary supplement available in the US market which has the capability for both reducing the endothelin 1 (ET1) enzyme as well as increasing the nitric oxide (NO) molecules, in order to increase the dilation of arteries and thereby improve blood flow. The presence of ET1 constricts the blood vessel, whereas the presence of NO dilates it. As a result of its “double-action” effect (proven by the Flow Mediated Dilatation (FMD) measurements in a double-blinded Placebo-controlled clinical trial*and in an in-vitro study** whose results were both published), VINIA® is uniquely positioned to combat the aging process caused by a reduction in blood flow.

Keep reading... Show less